Research
Hormonal
Caloric restriction (CR) extends lifespan and delays age-related diseases in mammals by modulating multiple metabolic pathways, including reduced insulin/IGF-1 signaling, lower thyroid hormone levels, and increased adiponectin, though its translation to human lifespan extension remains unproven.
While rigorous caloric restriction extends lifespan in animals, its effect on human lifespan is unproven. However, moderate caloric restriction combined with exercise can improve healthspan, reduce disease risk, and preserve muscle and bone density in middle-aged adults without the severe side effects of extreme dieting.
GoodQualifiesHIGH confidence
One of the most robust observations in the biology of aging is the ability of CR to delay or prevent a range of age-related processes and significantly extend life span... In mammals, the CR phenotype includes prevention of some of the potentially harmful changes that are typical of aging, such as increased adiposity and VF, or impaired hepatic and peripheral insulin action... whether it extends life span in these animals [nonhuman primates] is still open to debate... whether CR is capable of achieving life span extension in humans in addition to reducing disease-specific mortality risk remains to be resolved.
Why this rating
Strong evidence in rodents and non-human primates for healthspan and some lifespan metrics; human lifespan data is lacking.
Source
The Critical Role of Metabolic Pathways in Aging
Nir Barzilai et al. · Diabetes · 2012
DOI 10.2337/db11-1300
narrative_reviewCited 808×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Attenuated Insulin/IGF-1 Signaling (IIS) extends lifespan in model organisms, but in humans, low IGF-1 is associated with increased risk of cardiovascular disease, diabetes, and osteoporosis, creating a paradox where the mechanism that extends lifespan in animals may be detrimental in humans.Good
- Pharmacological inhibition of mTOR (e.g., rapamycin) extends lifespan in mice, but systemic blockade in humans may accelerate sarcopenia and frailty due to impaired muscle protein synthesis, requiring tissue-specific targeting.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →